Rheumatologe

Blog von Dr. med. Lothar M. Kirsch / 祁建德 // Poetry / Travels / Languages / Rheumatic Diseases / Tea

Seiten / Pages

▼
Showing posts with label ACR 2017. Show all posts
Showing posts with label ACR 2017. Show all posts
Saturday, March 17, 2018

Tanezumab in Patients with Knee or Hip Osteoarthritis at the 2017 ACR Annual Meeting in San Diego

›
You might recall that I had been very critical about tanezumab in osteoarthritis [1]. There has been one abstract/poster on tanez...
Thursday, March 8, 2018

Bimekizumab at the 2017 ACR Annual Meeting in San Diego

›
Bimekizumab (alternative names: CDP-4940 and UCB-4940) is a monoclonal antibody that targets IL-17A and IL-17F. Bimekizumab is deve...

Guselkumab at the 2017 ACR Annual Meeting in San Diego

›
Guselkumab is a monoclonal antibody that targets the p19 subunit of IL-23. Guselkumab is marketed by Janssen-Cilag under the name...

Risankizumab at the 2017 ACR Annual Meeting in San Diego

›
Risankizumab is a humanized IgG1 monoclonal antibody that inhibits interleukin-23 by specifically targeting the p19 subunit. It...
›
Home
View web version

Über mich / About myself / 自己的介绍

Rheumatologe
View my complete profile
Powered by Blogger.